news
Press release
 
February 27, 2014
Corindus Vascular Robotics Executive Participates in Forum Discussing Advancements in Human-Robotic Interaction

Corindus VP will lead discussion during Medical Development Group Forum on patient benefits of robotics, March 5

Waltham, MA, February 27, 2014Corindus Vascular Robotics, a leading developer of precision vascular robotics, will participate in the upcoming Medical Development Group (MDG) forum focusing on advances in human-robotic interaction. Jerry Jennings, Vice President of Research and Development for Corindus, will be speaking at the March 5 forum about the interaction between humans and the CorPath system, and the benefits that vascular robotics provides. The forum will take place at Constant Contact in Waltham, Mass. beginning at 5:30 p.m.

In many settings, robots are designed to operate autonomously. In medical procedures, robots are designed to enhance the capabilities of the physician and assist by adding a level of robotic precision to the control of devices. The MDG interactive discussion, titled Advances in Human-Robotic Interaction: Present and Future Impact on the Medical Field, will address the latest advances in robotics in health care.

“As a leader in the medical robotics space, we are pleased to have the opportunity to participate in the MDG forum highlighting the critical elements in the interaction between the expert staff in the cardiac cath lab and the CorPath robot.” said Jennings. “At Corindus, we spent years designing our system to fit into the existing cath lab workflow, so that physicians can easily incorporate CorPath into their practice.”

The CorPath System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath Robotic Angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimeter by millimeter precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

The MDG forum will be moderated by Dustin Burke, Senior Software Engineer at Aptima. The other speakers will include Scott Stropkay, Partner at Essential Design and Ingo lf Tuerk, M.D., Chief of Urology, St. Elizabeth’s Medical Center.

To learn more about this forum and upcoming events, visit Medical Development Group’s site.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window